Our Strategy

Getting to “Leading pharmaceutical company”

Our goal is to be a leading pharmaceutical company focused on the development, manufacturing, and commercialization of branded pharmaceutical products that use our proprietary extended-release drug delivery technology platform. The 505(b)(2) regulatory approval pathway allows for a potentially streamlined and targeted clinical development program. To achieve this goal, key elements of our business strategy include:

  • Leverage our commercialization capabilities in the U.S. with all of our product candidates that are FDA approved
  • Manufacture our proprietary products in our cGMP, FDA-inspected and DEA-registered manufacturing facilities
  • Utilize our proprietary technology platform to develop additional branded product candidates in Central Nervous System (CNS) and other therapeutic areas with unmet need
  • Continue to expand our robust intellectual property portfolio covering our novel extended-release drug delivery technology platform and products